14-day Premium Trial Subscription Sign Up For FreeGet Free

When Should You SELL Your Stocks? Click to watch.

Aerie Pharmaceuticals Stock Forecast


$6.81 (-4.62%)

Volume: 640.382k

Closed: May 20, 2022

Hollow Logo Score: -1.448

Aerie Pharmaceuticals Stock Forecast

$6.81 (-4.62%)

Volume: 640.382k

Closed: May 20, 2022

Score Hollow Logo -1.448

Aerie Pharmaceuticals Company Profile

2030 Main Street

Irvine CA 92614



Industry: Drug Manufacturers

Sector: Healthcare

Aerie Pharmaceuticals


Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, a once-daily eye drop, which has completed Phase III registration trials for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Roclatan, a once-daily eye drop to reduce IOP that has completed Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Irvine, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE